Benzinga -
- Henry Schein Inc (NASDAQ: HSIC) posts Q4 FY22 sales of $3.37 billion, beating the consensus of $3.34 billion.
- The 1.2% increase included a 1.8% decrease in local currencies excluding acquisitions, 1.1% growth from acquisitions, and a 3.0% decrease related to foreign currency exchange, while the extra week of sales contributed 4.9% to sales growth.
- Sales of PPE products and COVID-19 test kits in the fourth quarter were $254 million, which is $194 million lower than the prior-year period. Excluding sales of PPE products and COVID-19 test kits, fourth-quarter internal sales growth in local currencies was 5.0%.
- William Blair writes that management's 2023 EPS guidance of $5.25 to $5.42 is above the consensus but is not directly comparable since management is now excluding the amortization of intangibles.
- Sales growth is expected to be 1%-3% despite 30% to 35% declines in PPE and COVID sales.
- The analyst says the guidance is inline given the number of macro headwinds.
- Price Action: HSIC stock is down 7.55% at $81.94 on the last check Thursday.
| Feb 2022 | Morgan Stanley | Maintains | Underweight | |
| Feb 2022 | Credit Suisse | Maintains | Outperform | |
| Jan 2022 | Morgan Stanley | Initiates Coverage On | Underweight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.